Education
About Us
Working with TipRanks
Follow Us
Statera BioPharma (STAB)
OTHER OTC:STAB
Total Valuation
Statera BioPharma has a market cap or net worth of $14.28K. The enterprise value is $14.43M.
Market Cap$14.28K
Enterprise Value$14.43M
Share Statistics
Statera BioPharma has 71,416,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,416,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Statera BioPharma’s return on equity (ROE) is 111.23 and return on invested capital (ROIC) is -666.54%.
Return on Equity (ROE)111.23
Return on Assets (ROA)-8.24
Return on Invested Capital (ROIC)-666.54%
Return on Capital Employed (ROCE)-9.91
Revenue Per Employee0.00
Profits Per Employee-2.21M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Statera BioPharma is ―. Statera BioPharma’s PEG ratio is -0.00054.
PE Ratio―
PS Ratio0.00
PB Ratio-51.50
Price to Fair Value-51.50
Price to FCF-2.85
Price to Operating Cash Flow>-0.01
PEG Ratio-0.00054
Income Statement
In the last 12 months, Statera BioPharma had revenue of 0.00 and earned -174.41M in profits. Earnings per share was -4.97.
Revenue0.00
Gross Profit-488.31K
Operating Income-98.34M
Pretax Income-101.88M
Net Income-174.41M
EBITDA-170.65M
Earnings Per Share (EPS)-4.97
Cash Flow
In the last 12 months, operating cash flow was -12.86M and capital expenditures -103.37K, giving a free cash flow of -12.96M billion.
Operating Cash Flow-12.86M
Free Cash Flow-12.96M
Free Cash Flow per Share-0.18
Dividends & Yields
Statera BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.69
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Statera BioPharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Statera BioPharma as a current ratio of 0.37, with Debt / Equity ratio of -1037.04%
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.19
Net Debt to EBITDA-0.08
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Statera BioPharma has paid 72.53M in taxes.
Income Tax72.53M
Effective Tax Rate-0.71
Enterprise Valuation
Statera BioPharma EV to EBITDA ratio is -0.56, with an EV/FCF ratio of -3.35.
EV to Sales0.00
EV to EBITDA-0.56
EV to Free Cash Flow-3.35
EV to Operating Cash Flow-3.38
Balance Sheet
Statera BioPharma has $506.10K in cash and marketable securities with $7.41M in debt, giving a net cash position of -$6.90M billion.
Cash & Marketable Securities$506.10K
Total Debt$7.41M
Net Cash-$6.90M
Net Cash Per Share-$0.10
Tangible Book Value Per Share-$0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Statera BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―